ERA-话题@MedSci

#ERA#

425篇内容 | 3173人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1738955, encodeId=b4491e389550e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=General Psychia：或许，可以通过调节肠道细菌来缓解焦虑, objectType=article, longId=166846, objectId=f4e2166846cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4e2166846cd, replyNumber=0, likeNumber=71, createdTime=2020-03-04, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4e2166846cd, moduleTitle=General Psychia：或许，可以通过调节肠道细菌来缓解焦虑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4e2166846cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738922, encodeId=a5581e3892282, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Theravance生物制药宣布TD-8236进入I期临床试验, objectType=article, longId=154603, objectId=73d3154603fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73d3154603fa, replyNumber=0, likeNumber=72, createdTime=2019-10-27, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73d3154603fa, moduleTitle=Theravance生物制药宣布TD-8236进入I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73d3154603fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738911, encodeId=56051e389113c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=OMERACT超声倡议：SpA和PsA中以共识为基础的附着点炎超声定义与评分的可靠性, objectType=article, longId=151268, objectId=874e15126817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=874e15126817, replyNumber=0, likeNumber=63, createdTime=2019-09-29, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=874e15126817, moduleTitle=OMERACT超声倡议：SpA和PsA中以共识为基础的附着点炎超声定义与评分的可靠性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=874e15126817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738956, encodeId=0e621e3895662, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, objectType=article, longId=167543, objectId=1bb016e5435e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bb016e5435e, replyNumber=0, likeNumber=12, createdTime=2020-03-19, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bb016e5435e, moduleTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bb016e5435e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738916, encodeId=cacb1e3891696, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Mylan与Theravance制药的Yupelri被FDA批准用于COPD, objectType=article, longId=153277, objectId=e21c1532e78b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e21c1532e78b, replyNumber=0, likeNumber=83, createdTime=2019-01-13, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e21c1532e78b, moduleTitle=Mylan与Theravance制药的Yupelri被FDA批准用于COPD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e21c1532e78b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738928, encodeId=f8891e3892806, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=SCI 正式收录STTT《Signal Transduction and Targeted Therapy》, objectType=article, longId=157701, objectId=434115e701b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=434115e701b4, replyNumber=0, likeNumber=76, createdTime=2019-10-11, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=434115e701b4, moduleTitle=SCI 正式收录STTT《Signal Transduction and Targeted Therapy》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=434115e701b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738931, encodeId=4a5c1e38931fd, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Theravance Biopharma宣布Ampreloxetine III期研究治疗症状性神经源性直立性低血压患者入组, objectType=article, longId=159219, objectId=850a159219d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=850a159219d1, replyNumber=0, likeNumber=67, createdTime=2019-06-27, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=850a159219d1, moduleTitle=Theravance Biopharma宣布Ampreloxetine III期研究治疗症状性神经源性直立性低血压患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=850a159219d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738952, encodeId=46651e38952f2, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Promethera宣布在2a期临床研究中首次给药，评估世界首例肝干细胞疗法治疗晚期NASH患者, objectType=article, longId=165934, objectId=f5dd165934c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5dd165934c0, replyNumber=0, likeNumber=54, createdTime=2019-08-23, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5dd165934c0, moduleTitle=Promethera宣布在2a期临床研究中首次给药，评估世界首例肝干细胞疗法治疗晚期NASH患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5dd165934c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738893, encodeId=05811e38893e1, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Pharmacotherapy：利妥昔单抗vs 糖皮质激素治疗Graves眼眶病效果如何？, objectType=article, longId=141680, objectId=7f1914168040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f1914168040, replyNumber=0, likeNumber=64, createdTime=2018-12-05, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f1914168040, moduleTitle=Pharmacotherapy：利妥昔单抗vs 糖皮质激素治疗Graves眼眶病效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f1914168040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738947, encodeId=3de61e389471b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Journal for ImmunoTherapy of Cancer：CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据, objectType=article, longId=164218, objectId=ac0f164218bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0f164218bb, replyNumber=0, likeNumber=63, createdTime=2019-12-04, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0f164218bb, moduleTitle=Journal for ImmunoTherapy of Cancer：CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac0f164218bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738921, encodeId=56891e3892175, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Pharmacotherapy：前列腺癌患者雄激素剥夺治疗相关的主要长期副作用有哪些？, objectType=article, longId=154369, objectId=4bff154369ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bff154369ef, replyNumber=0, likeNumber=87, createdTime=2019-03-27, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bff154369ef, moduleTitle=Pharmacotherapy：前列腺癌患者雄激素剥夺治疗相关的主要长期副作用有哪些？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bff154369ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738891, encodeId=ef1c1e3889158, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Gene Therapy：好心帮倒忙，抑癌基因 TET2 或降低 CAR- T 疗效, objectType=article, longId=140825, objectId=6f67140825d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f67140825d2, replyNumber=0, likeNumber=91, createdTime=2019-02-11, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f67140825d2, moduleTitle=Gene Therapy：好心帮倒忙，抑癌基因 TET2 或降低 CAR- T 疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f67140825d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738886, encodeId=fc051e38886b9, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=英国的Enterprise Therapeutics公司筹集了2900万英镑用于推进呼吸道疾病的实验疗法, objectType=article, longId=135416, objectId=5056135416f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5056135416f5, replyNumber=0, likeNumber=45, createdTime=2018-12-28, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5056135416f5, moduleTitle=英国的Enterprise Therapeutics公司筹集了2900万英镑用于推进呼吸道疾病的实验疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5056135416f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738907, encodeId=42131e3890761, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=FDA批准Verastem公司PI3K 抑制剂Copiktra用于治疗血癌, objectType=article, longId=149621, objectId=d13714962110, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d13714962110, replyNumber=0, likeNumber=100, createdTime=2019-05-17, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d13714962110, moduleTitle=FDA批准Verastem公司PI3K 抑制剂Copiktra用于治疗血癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d13714962110)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738880, encodeId=caa91e388806f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=ALIMENT PHARM THERAP：早期维多珠单抗谷值水平预测炎症性肠病的粘膜愈合：一项多中心前瞻性观察性研究, objectType=article, longId=134459, objectId=e2521344596d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2521344596d, replyNumber=0, likeNumber=87, createdTime=2018-06-30, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2521344596d, moduleTitle=ALIMENT PHARM THERAP：早期维多珠单抗谷值水平预测炎症性肠病的粘膜愈合：一项多中心前瞻性观察性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2521344596d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738910, encodeId=cc971e389105e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=2018 ERAS/ESTS指南建议：促进肺外科手术后恢复, objectType=article, longId=151209, objectId=a773151209c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a773151209c2, replyNumber=0, likeNumber=12, createdTime=2019-02-26, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a773151209c2, moduleTitle=2018 ERAS/ESTS指南建议：促进肺外科手术后恢复, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a773151209c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738895, encodeId=05941e3889514, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=FDA拒绝INSYS Therapeutics的丁丙诺啡舌下喷雾治疗急性疼痛, objectType=article, longId=145381, objectId=2f6e14538120, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f6e14538120, replyNumber=0, likeNumber=62, createdTime=2018-11-23, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f6e14538120, moduleTitle=FDA拒绝INSYS Therapeutics的丁丙诺啡舌下喷雾治疗急性疼痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f6e14538120)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738896, encodeId=85c81e3889617, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=FYCOMPA（perampanel）已在PBS上用于未控制的PGTC癫痫发作的患者, objectType=article, longId=145543, objectId=c18c1455436d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c18c1455436d, replyNumber=0, likeNumber=68, createdTime=2018-09-01, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c18c1455436d, moduleTitle=FYCOMPA（perampanel）已在PBS上用于未控制的PGTC癫痫发作的患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c18c1455436d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738885, encodeId=8a891e3888583, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=vTv Therapeutics公司阿尔茨海默症候选药物临床试验失败, objectType=article, longId=135139, objectId=8b85135139e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b85135139e4, replyNumber=0, likeNumber=71, createdTime=2018-07-10, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b85135139e4, moduleTitle=vTv Therapeutics公司阿尔茨海默症候选药物临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b85135139e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738900, encodeId=6eab1e38900b7, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Theranostics：昆明动物所等揭示HUWE1维持肺癌发生机制, objectType=article, longId=145846, objectId=da5b1458463a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da5b1458463a, replyNumber=0, likeNumber=109, createdTime=2018-10-20, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da5b1458463a, moduleTitle=Theranostics：昆明动物所等揭示HUWE1维持肺癌发生机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da5b1458463a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ERA

2020-05-29

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

General Psychia：或许，可以通过调节肠道细菌来缓解焦虑

2020-03-04

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Theravance生物制药宣布TD-8236进入I期临床试验

2019-10-27

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

OMERACT超声倡议：SpA和PsA中以共识为基础的附着点炎超声定义与评分的可靠性

2019-09-29

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据

2020-03-19

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Mylan与Theravance制药的Yupelri被FDA批准用于COPD

2019-01-13

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

SCI 正式收录STTT《Signal Transduction and Targeted Therapy》

2019-10-11

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Theravance Biopharma宣布Ampreloxetine III期研究治疗症状性神经源性直立性低血压患者入组

2019-06-27

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Promethera宣布在2a期临床研究中首次给药，评估世界首例肝干细胞疗法治疗晚期NASH患者

2019-08-23

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Pharmacotherapy：利妥昔单抗vs 糖皮质激素治疗Graves眼眶病效果如何？

2018-12-05

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Journal for ImmunoTherapy of Cancer：CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据

2019-12-04

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Pharmacotherapy：前列腺癌患者雄激素剥夺治疗相关的主要长期副作用有哪些？

2019-03-27

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Gene Therapy：好心帮倒忙，抑癌基因 TET2 或降低 CAR- T 疗效

2019-02-11

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

英国的Enterprise Therapeutics公司筹集了2900万英镑用于推进呼吸道疾病的实验疗法

2018-12-28

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

FDA批准Verastem公司PI3K 抑制剂Copiktra用于治疗血癌

2019-05-17

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

ALIMENT PHARM THERAP：早期维多珠单抗谷值水平预测炎症性肠病的粘膜愈合：一项多中心前瞻性观察性研究

2018-06-30

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

2018 ERAS/ESTS指南建议：促进肺外科手术后恢复

2019-02-26

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

FDA拒绝INSYS Therapeutics的丁丙诺啡舌下喷雾治疗急性疼痛

2018-11-23

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

FYCOMPA（perampanel）已在PBS上用于未控制的PGTC癫痫发作的患者

2018-09-01

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

vTv Therapeutics公司阿尔茨海默症候选药物临床试验失败

2018-07-10

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Theranostics：昆明动物所等揭示HUWE1维持肺癌发生机制

2018-10-20

科室
- - 订阅+
  - 更多科室
工具
服务